Pomerantz probes Acadia over remlifanserin trial disclosure
Alpha Vantage · scanx.trade · · AI-summarised by FinFlash
Pomerantz LLP is investigating Acadia Pharmaceuticals for potential securities fraud after remlifanserin missed the primary endpoint in Phase 2 trials for Alzheimer's disease psychosis, sending shares down 12.78%. A key secondary endpoint reached statistical significance and Acadia will continue Phase 3, amending trials to drop the 30 mg dosage arm.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.